Gleevec Picks Up New Indication For Pediatric ALL
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA grants a new indication for Gleevec ahead of 2015 U.S. patent expiry, as Novartis plays up superiority of its follow-on Tasigna during its fourth-quarter earnings call.
You may also be interested in...
As Sun Sets On Gleevec, Novartis Looks To New Horizons In Oncology
The blockbuster leukemia drug will likely face generic competition in 2015, putting pressure on Novartis to bring new cancer drugs to market to make up for the lost sales. The company has several promising mid- to late-stage candidates in the pipeline, but developing another blockbuster the likes of Gleevec won’t be easy.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.